Department of General Practice, Lund University, Sweden.
Scand J Prim Health Care. 2011 Mar;29(1):57-62. doi: 10.3109/02813432.2011.554015.
To evaluate the prevalence of primary aldosteronism (PA) in newly diagnosed and untreated hypertensive patients in primary care using the aldosterone/renin ratio (ARR), and to assess clinical and biochemical characteristics in patients with high and normal ARR.
Patient survey study.
A total of 200 consecutive patients with newly diagnosed and untreated hypertension from six primary health care centres in Sweden were included.
ARR was calculated from serum aldosterone and plasma renin concentrations. The cut-off level for ARR was 65. Patients with an increased ARR were considered for confirmatory testing with the fludrocortisone suppression test (FST), followed by adrenal computed tomographic radiology (CT) and adrenal venous sampling (AVS).
Of 200 patients, 36 patients had an ARR > 65. Of these 36 patients, 11 patients had an incomplete aldosterone inhibition during FST. Three patients were diagnosed with an aldosterone producing adenoma (APA) and eight with bilateral adrenal hyperplasia (BHA). Except for moderately lower level of P-K in patients with an ARR > 65 and in patients with PA, there were no biochemical or clinical differences found among hypertensive patients with PA compared with patients without PA.
Eleven of 200 evaluated patients (5.5%) were considered to have PA. The diagnosis of PA should therefore be considered in newly diagnosed hypertensive subjects and screening for the diagnosis is warranted.
通过醛固酮/肾素比值(ARR)评估初级保健中初诊和未经治疗的高血压患者中原发性醛固酮增多症(PA)的患病率,并评估ARR 高和正常的患者的临床和生化特征。
患者调查研究。
共纳入瑞典六个初级保健中心的 200 名连续初诊和未经治疗的高血压患者。
ARR 由血清醛固酮和血浆肾素浓度计算得出。ARR 的截止值为 65。ARR 升高的患者考虑进行氟氢可的松抑制试验(FST)的确认性检查,随后进行肾上腺计算机断层扫描(CT)和肾上腺静脉取样(AVS)。
在 200 名患者中,有 36 名患者的 ARR>65。在这 36 名患者中,有 11 名患者在 FST 期间醛固酮抑制不完全。3 名患者被诊断为醛固酮分泌腺瘤(APA),8 名患者被诊断为双侧肾上腺增生(BHA)。除了 ARR>65 的患者和 PA 患者的 P-K 水平略低外,PA 患者与无 PA 的高血压患者之间没有发现生化或临床差异。
在评估的 200 名患者中,有 11 名(5.5%)被认为患有 PA。因此,应考虑在初诊的高血压患者中诊断 PA,并应进行诊断筛查。